SELLAS Life Sciences Group (NASDAQ:SLS) Trading 1.6% Higher – Time to Buy?

SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) shot up 1.6% during trading on Wednesday . The stock traded as high as $1.38 and last traded at $1.31. 1,674,518 shares changed hands during trading, an increase of 23% from the average session volume of 1,365,601 shares. The stock had previously closed at $1.29.

SELLAS Life Sciences Group Trading Up 1.6 %

The stock has a market cap of $119.01 million, a P/E ratio of -1.90 and a beta of 2.53. The company’s 50 day moving average price is $1.18 and its two-hundred day moving average price is $1.16.

SELLAS Life Sciences Group (NASDAQ:SLS) last issued its quarterly earnings results on Thursday, March 20th. The company reported ($0.08) earnings per share for the quarter, topping the consensus estimate of ($0.11) by $0.03. During the same quarter in the previous year, the firm posted ($1.34) EPS. On average, sell-side analysts anticipate that SELLAS Life Sciences Group, Inc. will post -0.57 earnings per share for the current year.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in the stock. Brooklyn FI LLC purchased a new position in shares of SELLAS Life Sciences Group during the 4th quarter valued at $677,000. Anson Funds Management LP raised its holdings in SELLAS Life Sciences Group by 50.2% during the fourth quarter. Anson Funds Management LP now owns 1,192,266 shares of the company’s stock valued at $1,240,000 after acquiring an additional 398,431 shares during the period. Northern Trust Corp lifted its position in shares of SELLAS Life Sciences Group by 33.6% in the fourth quarter. Northern Trust Corp now owns 134,721 shares of the company’s stock valued at $140,000 after acquiring an additional 33,878 shares in the last quarter. Geode Capital Management LLC boosted its stake in shares of SELLAS Life Sciences Group by 21.2% in the fourth quarter. Geode Capital Management LLC now owns 733,546 shares of the company’s stock worth $763,000 after acquiring an additional 128,355 shares during the period. Finally, Opus Capital Group LLC grew its position in shares of SELLAS Life Sciences Group by 5.5% during the fourth quarter. Opus Capital Group LLC now owns 238,500 shares of the company’s stock worth $248,000 after purchasing an additional 12,400 shares in the last quarter. 17.38% of the stock is currently owned by institutional investors.

SELLAS Life Sciences Group Company Profile

SELLAS Life Sciences Group, Inc, a late-stage clinical biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. The company’s lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase 3 clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer.